Gilead Sciences (NASDAQ:GILD) Price Target Raised to $115.00

Gilead Sciences (NASDAQ:GILD) had its price target lifted by investment analysts at JPMorgan Chase & Co. from $105.00 to $115.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 22.54% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. UBS Group boosted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Robert W. Baird boosted their target price on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Citigroup began coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target on the stock. Finally, Truist Financial upped their price target on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Price Performance

NASDAQ GILD opened at $93.85 on Wednesday. The stock’s fifty day moving average price is $92.00 and its 200 day moving average price is $85.44. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a market cap of $116.96 billion, a price-to-earnings ratio of 1,042.78, a PEG ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the prior year, the firm posted $2.29 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, equities research analysts forecast that Gilead Sciences will post 4.36 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 in the last quarter. 0.16% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors have recently bought and sold shares of GILD. Wingate Wealth Advisors Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter worth about $118,000. Savant Capital LLC boosted its holdings in shares of Gilead Sciences by 2.0% during the fourth quarter. Savant Capital LLC now owns 27,921 shares of the biopharmaceutical company’s stock worth $2,579,000 after purchasing an additional 558 shares during the period. Wagner Wealth Management LLC lifted its position in shares of Gilead Sciences by 8.5% in the fourth quarter. Wagner Wealth Management LLC now owns 8,710 shares of the biopharmaceutical company’s stock worth $805,000 after buying an additional 684 shares during the last quarter. Angeles Wealth Management LLC acquired a new stake in Gilead Sciences in the 4th quarter worth $200,000. Finally, Stone Summit Wealth LLC increased its stake in Gilead Sciences by 6.3% in the fourth quarter. Stone Summit Wealth LLC now owns 30,503 shares of the biopharmaceutical company’s stock valued at $2,818,000 after acquiring an additional 1,798 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.